Marc G. Taylor, Ph.D.

Houston TX Area
310-600-9973
marcgtaylor@hotmail.com

OBJECTIVE: Biotechnology/CRO R&D Management with a role in Scientific Strategic Leadership
SKILL SETS:
CRO & Biotechnology Team Management
IVD Assay Development Project Management
Medical Liaison & KOL Communication
Business Development Technical Lead
Federal & State Research Grant Writing
Medical & Molecular Diagnostics Devices
Nucleic Acid Testing & Genomics
Microarrays & Microfluidics
Drug Discovery High-Throughput Screening (HTS)
Protein Chemistry & Enzymology
WORK EXPERIENCE:
ApoCell, Inc. (Houston TX) 2014
Scientific Director
Led CLIA-approved contract research organization (CRO) scientific team performing cellular and molecular
analysis of circulating tumor cells (CTCs) for pharmaceutical companies and key opinion leader (KOL) clients.
Directed research efforts of six (6) senior scientists (5 Ph.D.s) in the isolation and characterization of rare cancer cell
types, including CTCs. Downstream analyses of cancer biomarkers (proliferation, DNA damage, signal transduction,
etc.) included both cellular (immunofluorescence (IF) by laser scanning cytometry (LSC), fluorescence in situ
hybridization (FISH), immunohistochemistry (IHC)) and molecular diagnostics-based methods (quantitative real-time
PCR (qRT-PCR) and next generation sequencing (NGS)).
Presided over experimental designs, biomarker analyses, and budgets for over 30 client-sponsored cancer research
projects associated with all phases of preclinical and clinical development.
Co-Authored three (3) state and federal grants for investigation of rare cell protein phenotypes and molecular markers.

BioSapient Consulting, Inc. (Newark DE) 2010- 2013
Principal Biotechnology Consultant
Provided expert scientific advice on IVD trends, research and development of novel biomarkers and panels,
microfluidics and microarrays, macromolecules, and reaction kinetics.
Offered counsel on IVD advancements, medical devices, molecular diagnostics, nanotechnology, nutrition and
metabolism, and biomarkers of cancer, cardiovascular disease, diabetes, infectious disease, and multiple sclerosis (MS).

Siemens Healthcare Diagnostics (Newark DE, Los Angeles CA) 2003 2010
Director in Assay Development, Director, Biomarker Discovery / Assessment, etc.
Directed transcriptomics-driven biomarker discovery program and immunoassay development projects. Led
efforts to assess new biomarkers for potential collaborations and licensing.
Directed cross-functional team in the development of an FDA-approved immunoassay on an automated instrument,
with a projected revenue of US$27-33MM. Led all aspects of GLP/GMP project management and coordination with
Manufacturing, Regulatory, QA, Engineering, Software, Finance, Clinical Affairs, Product Support, and Marketing.
Directed research of 8-15 R&D scientists in cancer (breast, ovarian, prostate, lung) and cardiovascular disease biomarker
discovery collaboration, which led to the identification of four (4) novel splice variant proteins.
Assessed over 120 IVD biomarkers for scientific and strategic feasibility. Tests targeted cancers, heart disease, as well as
neurological (stroke, brain injury, Alzheimer's), autoimmune (diabetes, MS, etc.), hormonal, and infectious diseases.
Reports and presentations were instrumental to more than 50 go/no go decisions regarding diagnostic collaborative
efforts and synergies with imaging technologies.
Established over 60 communications with KOLs in clinical therapy, diagnostics, imaging, and biomarker discovery.
marcgtaylor@hotmail.com Marc G. Taylor, Ph.D. cell phone: 310-600-9973


Conceived and designed six (6) biomarker panel studies for detection of early and recurrent cancers (breast, colorectal,
lung), as stand-alone multi-analyte IVD efforts and cooperatively with In Vivo molecular imaging technologies.
Advised R&D on biomarker discovery technologies, cancer and cardiac markers, mathematical modeling of biochemical
processes, enzymology, protein structure and purification, and macromolecular conjugation.
Beckman Coulter, Inc. (Fullerton CA) 2001-2003
Staff Scientist and Team Leader, Biological Systems
Directed kinetics and precision teams. Formulated two new products with no new manufacturing via
invention of method for monitoring thermostable DNA polymerases.
Invented DNA polymerase kinetic assay to assess inconsistent peak heights during DNA sequencing. Kit reformulation
eliminated 75% of peak-to-peak variance, greatly improving automated sequence analysis.
Formulated Beckman's first SNP detection genomics kit employing only current product line reagents.
Led kinetics and precision teams in development of 42-spot multiplexed DNA-addressable protein microarray.
Decreased microarray analysis time by 90-99% by design of eight (8) computational spreadsheets.

Caliper Technologies (now, PerkinElmer

) (Mountain View CA) 1999-2001

Senior Research and Development Scientist
Developed microfluidic chip high-throughput screening (HTS) methods for pharmaceutical manufacturers
seeking to streamline and accelerate primary drug screening of compound libraries.
Formulated six (6) HTS microfluidics methods (> 10,000 tests/day/chip) to identify pharmaceutical lead compounds.
Devised Calipers first two (2) immobilized enzyme microfluidic chip assays for drug screening.
Created computational spreadsheet tools for design and analysis of enzymatic and ligand binding assays, compatible
with UV-Vis absorbance, chemiluminescence, fluorescence, and fluorescence polarization spectrophotometry.
Consulted on enzyme kinetics, mechanisms, and novel formats for screening expanded array of protein targets.

Dade Behring Inc. (now, Siemens) (San Jose CA) 1993-1999
Senior Research Scientist
Identified novel disease markers, invented patented molecular diagnostics methodologies, developed
immunoassays, and optimized protein chemistry and conjugation methods.
Identified a novel cardiac ischaemia marker, leading to the foundation of a new medical diagnostics company valued at
US$22MM (purchase price in 2005).
Co-Invented a molecular diagnostics assay panel to screen adult carriers and affected newborn children for more than
150 known mutations of cystic fibrosis, effective for at least 80% of known alleles. Patented a method to increase
sensitivity (up to 4-fold) for a genomic mutation and SNP detection system.
Co-Developed two (2) high-specificity osteoporosis immunoassays. Re-formulated the protein calibrator purification
protocol, resulting in a 75% decrease in total preparation time, with enhanced yield and purity.

EDUCATION & CERTIFICATIONS:
"CDRH Learn" Medical Device Training & Continuing Education (28 Certificates) U.S. F.D.A.
Post-Doctoral Research Fellow University of California, Berkeley CA
Created the first protein-protein transition state model using over 25 specific mutations of a protein antigen. (Cover: Prot. Sci.)
Ph.D. & M.S. in Biological Chemistry University of Michigan, Ann Arbor MI
Elucidated the chemical and kinetic mechanism and structure-function relationships of an FAD-dependent aromatic oxygenase.
B.Sc. in Biology Massachusetts Institute of Technology (M.I.T.), Cambridge MA